Gilenya (fingolimod) received its initial U.S. Food and Drug Administration (FDA) approval on September 8, 2010 [1]. This approval was for the treatment of relapsing forms of multiple sclerosis (MS) in patients [1].
When did Gilenya become available in Europe?
In Europe, Gilenya was approved by the European Medicines Agency (EMA) in October 2011 [2]. This marked its availability for use in European Union member states [2].
What forms of multiple sclerosis does Gilenya treat?
Gilenya is approved for treating relapsing forms of multiple sclerosis. This includes clinically isolated syndrome, relapsing-remitting multiple sclerosis, and active secondary progressive multiple sclerosis [1][2].
What is the mechanism of action for Gilenya?
Gilenya works by acting as a sphingosine-1-phosphate (S1P) receptor modulator [3]. It temporarily sequesters lymphocytes in secondary lymphoid organs, preventing them from entering the central nervous system (CNS) and causing inflammatory damage [3]. This mechanism reduces the frequency of relapses in patients with relapsing MS [3].
What are the key safety concerns associated with Gilenya?
Potential side effects and safety concerns with Gilenya include infections, bradycardia (slow heart rate) and AV block upon initiation, liver enzyme elevations, and macular edema [1]. There is also a risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection [1]. Patients are monitored closely for these effects.
How does Gilenya's patent protection impact its market availability?
The original patent for Gilenya has expired, opening the door for potential generic competition. Patent expiry dates can vary by region and any subsequent patent challenges or extensions [4]. DrugPatentWatch.com tracks these patent timelines and potential market entry dates for generic versions [4].
When might generic versions of Gilenya become available?
Following the expiry of its primary patents, generic versions of Gilenya have begun to enter the market in some regions. Specific timelines for generic availability depend on patent litigation outcomes and regulatory approvals in different countries [4].